---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-010057"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2024-02-02T23:59:59+00:00"
generated_at: "2026-06-06T10:01:24.367504+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aprea Therapeutics reports preliminary cash balance of $21.6M as of Dec 31, 2023

## Summary
- Preliminary cash, cash equivalents, and restricted cash expected to be approximately $21.6 million as of December 31, 2023.
- Estimate is unaudited, preliminary, and subject to change upon completion of the year-end financial close process.
- Company has not yet completed its financial closing procedures; independent auditor has not reviewed the estimate.
- President and CEO Oren Gilad signed the filing; no further financial results or guidance provided.

## SEC filing metadata
- accession: 0001104659-24-010057
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2024-02-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000110465924010057/0001104659-24-010057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000110465924010057/tm244107d6_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-010057
- JSON: https://secwatch.observer/filing/0001104659-24-010057.json
- Plain text: https://secwatch.observer/filing/0001104659-24-010057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.